122 related articles for article (PubMed ID: 38648575)
21. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
De La Fouchardière C; Malka D; Cropet C; Chabaud S; Raimbourg J; Botsen D; Launay S; Evesque L; Vienot A; Perrier H; Jary M; Rinaldi Y; Coutzac C; Bachet JB; Neuzillet C; Williet N; Desgrippes R; Grainville T; Aparicio T; Peytier A; Lecomte T; Roth GS; Thirot-Bidault A; Lachaux N; Bouché O; Ghiringhelli F
J Clin Oncol; 2024 Mar; 42(9):1055-1066. PubMed ID: 38232341
[TBL] [Abstract][Full Text] [Related]
24. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Sachdev JC; Munster P; Northfelt DW; Han HS; Ma C; Maxwell F; Wang T; Belanger B; Zhang B; Moore Y; Thiagalingam A; Anders C
Breast Cancer Res Treat; 2021 Feb; 185(3):759-771. PubMed ID: 33201358
[TBL] [Abstract][Full Text] [Related]
28. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
[TBL] [Abstract][Full Text] [Related]
29. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
[TBL] [Abstract][Full Text] [Related]
32. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
33. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Lung Cancer; 2011 Dec; 74(3):481-5. PubMed ID: 21620511
[TBL] [Abstract][Full Text] [Related]
35. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
[TBL] [Abstract][Full Text] [Related]
37. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
38. Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
He M; Wu B; Liu Q; Fang Z; Liu M; Yi F; Wei Y; Peng J; Zhang W
Chemotherapy; 2021; 66(4):113-123. PubMed ID: 34515066
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
